by Team Small News | Oct 7, 2025 | Dr Reddy's
On Monday, Donald Trump will be inaugurated for his second term as the President of the United States. The event is expected to be a significant one, with several key activities and attendees. Trump plans to sign numerous executive orders on his first day in office,...
by Team Small News | Sep 25, 2025 | Dr Reddy's
A groundbreaking agreement has been reached to make a revolutionary HIV prevention treatment, lenacapavir, more affordable and accessible to low- and middle-income countries. The treatment, which is nearly 100% effective, will be available at a cost of $40 per person...
by Team Small News | Sep 23, 2025 | Dr Reddy's
The active pharmaceutical ingredients (API) industry in India is expected to experience significant growth, with a projected value of INR 1.82 trillion by 2030, expanding at a compound annual growth rate (CAGR) of 8.26% during the 2025-2030 period. In 2023, the...
by Team Small News | Sep 22, 2025 | Dr Reddy's
The European Medical Agency’s (EMA) committee has recommended AVT03, a biosimilar of Prolia (denosumab) and Xgeva (denosumab), for marketing authorization in the European Economic Area (EEA). The positive opinion from the EMA’s Committee for Medicinal...
by Team Small News | Sep 13, 2025 | Dr Reddy's
The U.S. Food and Drug Administration (FDA) has issued a Form 483 with five observations to Dr. Reddy’s Laboratories, a generic drugmaker, following a pre-approval inspection (PAI) of their biologics manufacturing facility in Hyderabad, India. The inspection...
by Team Small News | Sep 6, 2025 | Dr Reddy's
Dr. Reddy’s Laboratories, a prominent pharmaceutical company, has received 7 observations from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) facility in Mirfield, UK. The USFDA conducted an inspection of...